A delegation by the World Health Organisation (WHO) has visited on Wednesday Biogeneric Pharma’s (BGP)factory in the Egyptian city of 10th of Ramadan.
WHO has chosen BGP as one of the first recipients of the transfer of mRNA technology to become a regional centre for the manufacture of Corona Virus vaccine and other vaccines for the African continent, Ashraf Abdel-Aal, Vice-Chairman of BGP, said.
The plant is one of the most recent factories for the production of vital medicines and vaccines in Egypt and the Middle East, which expected to online soon.
The factory located on an area of 19,500 square metres that expected as it includes the latest international technologies for manufacturing, high quality, and the effectiveness of pharmaceutical products to ensure the best quality for the patients, Mohamed Rabie Chairman of BGP, said.
WHO’s delegation praised during the visit the technical capabilities of the factory and its employees.
Abel Aal stressed that choosing Egypt among the first 6 countries to receive this mRNA technology came as a result of the political leadership efforts made during the African/European summit in the Belgian capital. In addition to that, the state’s orientation to support and localize the biopharmaceutical industry and high-tech vaccines in Egypt.
